Rajasthan Health Minister Gajendra Singh Khimsar recently affirmed the safety of a cough syrup, Dextromethorphan Hydrobromide (DXM HBr), despite allegations linking it to three child fatalities in the state. Consequently, the minister stated that both the state drug controller and the Rajasthan Medical Services Corporation Limited (RMSCL) thoroughly tested the medicine, with both reports confirming it was not faulty.
Understanding Cough Syrup Safety Concerns
The minister explained that the three deceased children had pre-existing comorbidities. Furthermore, he clarified that parents administered the cough syrup to the children without a doctor’s prescription. Khimsar emphasized the risks of giving adult medication to children, especially a two-year-old. Preliminary investigations in all three death cases did not confirm doctor-prescribed or administered Dextromethorphan Hydrobromide.
Kaysons Pharma: Precautionary Ban and Past Issues Affecting Cough Syrup Safety
Following clean test reports for the cough syrup, Kaysons Pharma, the supplier, received a clean chit for the specific batch. However, as a precautionary measure, the department suspended the use and distribution of all 19 medicines supplied by Kaysons Pharma until further orders. This decision comes despite the minister’s assertions regarding the cough syrup’s safety. Notably, Kaysons Pharma has a history of quality concerns; since 2012, 42 out of 10,119 tested samples were found substandard. During the COVID-19 period alone, 39 samples of one medicine failed quality tests. Moreover, the Rajasthan government suspended the state drug controller amidst these events, citing alleged misconduct.
Government Actions and Public Assurance on Drug Safety
The minister reassured the public that the government remains open to external testing of these medicines if doubts persist. He also mentioned forming a second committee to thoroughly check all of Kaysons Pharma’s medicines. Officials reported that 1.33 lakh people consumed the medicine since its approval, and approximately 14,000 people took it in the last month. Apart from the three child deaths, no other fatalities from this medicine have been reported, even though doctors prescribed it at various health centers.
Medical authorities reiterate the Union government’s 2021 advisory against administering Dextromethorphan to children under four years. The Drug Controller General of India clarified that it should typically be given only to children above five years, and never to those under two. This highlights the importance of understanding safe medication practices, especially for vulnerable populations. For professionals looking to deepen their knowledge in this area, the Certification Course In Safe Prescribing offers valuable insights.
Frequently Asked Questions
Q1: Why did Rajasthan’s Health Minister declare the cough syrup safe despite child deaths?
A: Rajasthan Health Minister Gajendra Singh Khimsar stated that both the state drug controller and RMSCL tested the cough syrup, Dextromethorphan Hydrobromide, finding it not faulty. He attributed the child deaths to pre-existing comorbidities and parents administering the medicine without a doctor’s prescription.
Q2: Why were 19 medicines from Kaysons Pharma banned if the cough syrup tested clean?
A: The ban on 19 medicines from Kaysons Pharma was a precautionary measure, even after the specific cough syrup batch reportedly tested clean. This action was taken in light of past quality issues with Kaysons Pharma, where 42 out of 10,119 samples failed quality tests since 2012.
Q3: What are the current recommendations for Dextromethorphan Hydrobromide use in children?
A: The Union government’s 2021 advisory suggests not administering Dextromethorphan to children under four years. The Drug Controller General of India further advises that the syrup should generally be given only to children above five years and is strictly not recommended for children under two years of age. Understanding pediatric medication guidelines is crucial, and professionals can enhance their expertise through the International Post Graduate Program In Pediatrics.
References
- Cough syrup not faulty, pharma firm’s 19 drugs banned as precaution: Rajasthanhealth minister – ETHealthworld.
- Rajasthan cough syrup row: 11 child deaths trigger suspension of drug controller, Kaysons Pharma drugs pulled from market – The Economic Times.
- Rajasthan bans 19 medicines by Kayson Pharma after death of two children.
- Rajasthan suspends drug controller, cracks down on key cough syrup supplier – India Today.
- Drugs from banned pharma co failed quality tests in the past | Jaipur News – Times of India.
- The Hindu – Rajasthan government suspends drug controller, halts distribution of Kaysons Pharma drugs.
- Cough syrup that killed child in Rajasthan failed 40 tests but still sold – India Today.
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.